1 Title page

- 2 **Type of manuscript:** Original article.
- 3 **Title**: Altered blood microbiome in patients with HCV-related decompensated cirrhosis.
- 4 **Running head**: Blood microbiome in cirrhosis
- 5 Authors: Oscar BROCHADO-KITH ^{1,2}; Marta RAVA ^{3,2}; Juan BERENGUER ^{2,4,5}; Juan GONZÁLEZ-
- 6 GARCÍA ^{6,7}; David ROJO ⁸; Cristina DÍEZ ^{2,4,5}, Victor HONTAÑON ^{6,7}; Ana VIRSEDA-BERDICES ^{1,2};
- 7 Luis IBAÑEZ-SAMANIEGO ⁹; Elba LLOP-HERRERA ¹⁰; Antonio OLVEIRA ¹¹; Leire PEREZ-
- 8 LATORRE^{2, 4,5}; Coral BARBAS⁸; Amanda FERNÁNDEZ-RODRÍGUEZ^{1,2}; Salvador RESINO^{1,2,†,*};
- 9 María Angeles JIMÉNEZ-SOUSA 1.2.^{†,*} and the ESCORIAL Study Group,
- 10 (†), The authors contributed equally to this work. (*), Corresponding author.

11 Authors' Affiliations:

- 12 (1) Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto
- 13 de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
- 14 (2) Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC),
- 15 Instituto de Salud Carlos III. Madrid. Spain.
- 16 (3) Unidad de la Cohorte de la Red de Investigación en Sida (CoRIS). Centro Nacional de
- 17 Epidemiologia, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
- 18 (4) Unidad de Enfermedades Infecciosas/VIH; Hospital General Universitario "Gregorio
- 19 Marañón", Madrid, Spain.
- 20 (5) Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
- 21 (6) Servicio de Medicina Interna-Unidad de VIH. Hospital Universitario La Paz. Madrid, Spain.
- 22 (7) Instituto de Investigación Sanitaria La Paz (IdiPAZ). Madrid, Spain.

23	(8) Centre of Metabolomics and Bioanalysis (CEMBIO), Facultad de Farmacia, Universidad San
24	Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28060 Boadilla del Monte, Spain
25	(9) Servicio de Aparato Digestivo, Hospital General Universitario "Gregorio Marañón", Madrid,
26	Spain.
27	(10) Departamento de Gastroenterología; Hospital Universitario Puerta de Hierro-Majadahonda;
28	Majadahonda, Madrid; Spain.
29	(11) Servicio de Aparato Digestivo, Hospital Universitario La Paz, Madrid, Spain
30	
31	*Corresponding author: Maria Angeles Jiménez-Sousa; Centro Nacional de Microbiología,
32	Instituto de Salud Carlos III (Campus Majadahonda); Carretera Majadahonda-Pozuelo, Km 2.2;
33	28220 Majadahonda (Madrid); Phone: +34918223862. E-mail: jimenezsousa@isciii.es.
34	Co-Corresponding author: Salvador Resino García; Centro Nacional de Microbiología,
35	Instituto de Salud Carlos III (Campus Majadahonda); Carretera Majadahonda-Pozuelo, Km 2.2;
36	28220 Majadahonda (Madrid); Phone: +34918223266. E-mail: <u>sresino@isciii.es.</u>
37	
38	Declarations
39	Consent for publication
40	Not applicable
41	Availability of data and materials
42	The datasets used and/or analyzed during the current study are available from the
43	corresponding author upon reasonable request.
44	The raw sequences are publicly available at the European Nucleotide Archive repository
45	(ENA; https://www.ebi.ac.uk/) under the accession number PRJEB65371.

46 **Competing interests**

47 The authors declare that they have no competing interests.

The funding sources played no role in the study's design, collection, analysis, interpretation of

49 the data, or manuscript writing.

50 Funding

51 This study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant numbers

52 CP17CIII/00007, PI18CIII/00028 and PI21CIII/00033 to MAJS, PI17/00657 and PI20/00474

to JB, PI17/00903 and PI20/00507 to JGG, and PI17CIII/00003 and PI20CIII/00004 to SR)

and Ministerio de Ciencia e Innovación (PID2021–1267810B-I00 funded by

55 MCIN/AEI/10.13039/501100011033 and by "ERDF A way of making Europe" to AFR). The

56 study was also funded by CIBER - Consorcio Centro de Investigación Biomédica en Red - (CB

57 2021; CB21/13/00044), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and

58 Unión Europea - NextGenerationEU. CB and DR acknowledge funding from the Ministerio de

59 Ciencia, Innovación y Universidades (RTI2018-095166-B-I00). MAJS and MR are Miguel

60 Servet researchers supported and funded by ISCIII (grant numbers: CP17CIII/00007 to MAJS

61 and CP19CIII/00002 to MR).

62 Acknowledgments

This study would not have been possible without the collaboration of all the patients, medical
and nursery staff, and data managers who participated in the project. We want to particularly
acknowledge the support of the HIV BioBank, integrated into the Spanish AIDS Research
Network and all collaborating Centres, for the generous contribution with clinical samples for
the present work (see Appendix). The HIV BioBank is supported by Instituto de Salud Carlos
III, Spanish Health Ministry (Grant nº RD06/0006/0035, RD12/0017/0037 and
RD16/0025/0019) as part of the Plan Nacional R + D + I and cofinanced by ISCIII-

70 Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER)". The

- 71 RIS Cohort (CoRIS) is funded by the Instituto de Salud Carlos III through the Red Temática de
- 72 Investigación Cooperativa en SIDA (RIS C03/173, RD12/0017/0018 and RD16/0002/0006)
- as part of the Plan Nacional R+D+I and cofinanced by ISCIII-Subdirección General de
- 74 Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER).

75 Authorship contribution

- 76 Funding body: MAJS, SR.
- 77 Study concept and design: MAJS.
- 78 Patients' selection and clinical data acquisition: CD, VH, JB, JGG, LIS, ELH, AO, LPL.
- 79 Sample preparation, and biomarker analysis: OBK, AVB, AFR, DR, CB.
- 80 Statistical analysis and interpretation of data: OBK, MR, MAJS.
- 81 Writing of the manuscript: OBK, MAJS.
- 82 Critical revision of the manuscript for relevant intellectual content: JB, JGG, DR, CB, AFR, MR,
- 83 SR.
- 84 Supervision and visualization: MAJS.
- 85 All authors read and approved the final manuscript.

86 Ethical Approval statement

- 87 The study received the approval of the Research Ethics Committee of the Instituto de Salud
- 88 Carlos III (CEI42_2020, CEI41_2014).

89 Appendix

- 90 The ESCORIAL study group.
- 91 Hospital General Universitario Gregorio Marañón (Madrid, Spain): Cristina Díez, Luis
- 92 Ibáñez, Leire Pérez-Latorre, Diego Rincón, Teresa Aldámiz-Echevarría, Vega Catalina, Pilar
- 93 Miralles, Teresa Aldámiz-Echevarría, Francisco Tejerina, María C Gómez-Rico, Esther Alonso,
- 94 José M Bellón, Rafael Bañares, and Juan Berenguer.

95	Hospital Universitario La Paz/IdiPAZ (Madrid, Spain): José Arribas, José I Bernardino,
96	Carmen Busca, Javier García-Samaniego, Víctor Hontañón, Luz Martín-Carbonero, Rafael
97	Micán, María L Montes-Ramírez, Victoria Moreno, Antonio Olveira, Ignacio Pérez-Valero,
98	Eulalia valencia, and Juan González-García.
99	Hospital Universitario Puerta de Hierro (Madrid, Spain): Elba Llop and José Luis Calleja.
100	Hospital Universitario Ramón y Cajal (Madrid, Spain): Javier Martínez and Agustín Albillos
101	Fundación SEIMC/GeSIDA (Madrid, Spain): Marta de Miguel, María Yllescas, and Herminia
102	Esteban.
103	

104 Abstract

105 **Background**: Altered bacterial translocation is associated with transitioning from

106 compensated to decompensated cirrhosis. Thus, we aimed to study differences in the blood

107 microbiome of HCV-infected patients with and without hepatic decompensation.

108 Methods: We conducted a cross-sectional study in patients with advanced HCV-related cir-

109 rhosis with or without human immunodeficiency virus (HIV) infection (n=88). MiSeq Illumina

110 technology for bacterial 16S rRNA sequencing was used. Non-targeted metabolomics was per-

111 formed by GC-MS and LC-MS ESI+ and ESI-

112 **Results**: Patients with decompensated cirrhosis had lower levels of richness (Chao1), and

alpha diversity (Shannon and Simpson indexes) at phylum level, than patients without

114 decompensation. Likewise, we observed significant differences in beta diversity between

115 groups at phylum, class and order levels, being lower in decompensated cirrhotic patients.

Higher relative abundance of Proteobacteria (Fold Change (FC)=1.54, p=0.012),

Alphaproteobacteria (FC=1.57, p=0.016) and Sphingomonadales (FC=1.61, p=0.050) were

significantly associated with hepatic decompensation. The phylum Proteobacteria was posi-

tively correlated with ethanolamine and oleic acid (p=0.005 and p=0.004, respectively) and

- negatively with p-cresol (p=0.006). In addition, the order Sphingomonadales was also nega-
- 121 tively correlated with p-cresol (p=0.001).
- 122 **Conclusions**: Blood microbial diversity was significantly decreased in patients with decom-
- 123 pensated cirrhosis, who presented an enrichment of Proteobacteria, Alphaproteobacteria, and
- 124 Sphingomonadales, compared to patients with compensated cirrhosis.
- 125

126 Key Words

127 Chronic hepatitis C; HIV; cirrhosis; decompensation; microbiome; metabolome

128 Background

Hepatitis C virus (HCV) infection is considered one of the most notable causes of chronic liver 129 disease worldwide. Without antiviral therapy, about 5-20% of HCV-infected patients will 130 develop cirrhosis, increasing the risk of liver failure, hepatic decompensation, hepatocellular 131 132 carcinoma (HCC), and death. Hepatic decompensation is considered the most important cause of hospitalization among cirrhotic patients and a major risk factor for death [1]. 133 Decompensated cirrhosis has an annual mortality rate of 57%, and 30% mortality is 134 associated with acute decompensating events [2]. Traditionally, non-invasive indexes have 135 been used to triage patients with advanced liver diseases. Among them, the Child-Turcotte-136 Pugh (CTP) score is an essential indicator of severity, determining the cirrhosis status and 137 138 predicting morbidity and mortality. 139 The gut microbiota and bacterial translocation may influence liver disease progression in 140 patients with viral hepatitis [3]. Likewise, gut microbiota dysbiosis and sustained bacterial 141 translocation have been observed among people living with human immunodeficiency virus 142 (HIV) despite the use of antiretroviral therapy (ART) [4]. In this setting, bacterial overgrowth 143 increases intestinal permeability, and defects in gut-associated lymphatic tissue in patients 144 with advanced liver disease promote impaired bacterial translocation, which leads to severe 145 liver damage by several mechanisms related to persistent immune activation and inflammation [5]. Thus, altered bacterial translocation is associated with transitioning from 146 147 compensated to decompensated cirrhosis [6]. In this context, the presence in the blood of certain bacteria or bacterial products, and the 148 149 finding of specific microbiome patterns, could constitute an innovative approach for a better understanding of the pathogenesis of advanced HCV-related cirrhosis. So far, scarce studies 150 have investigated the blood microbiome in decompensated cirrhotic patients. Trakova et al. 151 [7] found a markedly higher number of bacterial species than control individuals. Alvarez-152

153	Silva et al. [8] described a relationship between the microbiota composition and systemic
154	inflammation in the blood. However, to our knowledge, none of the previous studies focused
155	on studying the role of the blood microbiome among HCV-infected patients with hepatic
156	decompensation.
157	Objective
157 158	Objective We aimed to study differences in the blood microbiome of HCV-infected patients with and
157 158 159	Objective We aimed to study differences in the blood microbiome of HCV-infected patients with and without hepatic decompensation.

162 Methods

163 **Study subjects**

We performed a cross-sectional study in patients with advanced HCV-related cirrhosis with or 164 without HIV, recruited at four tertiary referral hospitals in Madrid (Spain) between January 165 166 2015 and June 2016. The study received the approval of the Research Ethics Committee of the Instituto de Salud Carlos III (CEI42 2020, CEI41 2014) and was carried out following the 167 Declaration of Helsinki. All participants of the study gave their written informed consent. 168 The selection criteria were: 1) demonstrable active HCV infection by polymerase chain 169 reaction (PCR); 2) advanced cirrhosis defined by any of the following criteria: i) prior history 170 of ascites, bleeding esophageal varices, or hepatic encephalopathy; ii) liver stiffness ≥ 25 kPa; 171 iii) CTP \geq 7); and/or iii) clinically significant portal hypertension defined as an hepatic venous 172 pressure gradient (HVPG) \geq 10 mmHg; 3) available CTP score; 4) available blood sample for 173 174 microbiome analysis. HIV/HCV-coinfected patients had a stable ART for over six months and undetectable plasma HIV viral load (<50 copies/mL). 175

176 Samples

177 Approximately 30-40 mL of whole blood was collected from each patient in EDTA tubes,

178 which were sent to the HIV Biobank (http://hivhgmbiobank.com/?lang=en), where they were

179 processed and stored at -80 °C until use. The epidemiological and clinical variables were

180 collected using an online form within each center, which fulfilled data confidentiality

181 requirements.

182 **Outcome variable**

The outcome was hepatic decompensation, defined as a CTP score ≥ 7. CTP score was
calculated from five routine laboratory parameters and clinical measures of liver disease

185 (serum albumin, total bilirubin, international normalized ratio (INR), ascites, and hepatic

186 encephalopathy) (https://www.hepatitisc.uw.edu/page/clinical-calculators/ctp).

187 Blood microbiome

Whole blood samples were used for DNA extraction and subsequent 16S targeted
metagenomic sequencing in a strictly controlled environment. It was carried out at Vaiomer

190 (Toulouse, France), a biotech company expert in tissue and blood microbiota, which uses a

rigorous contamination-aware approach, described and discussed elsewhere [9-11].

192 DNA was extracted from 50 μ l of each whole blood sample using an optimized tissue-specific

technique, as previously described [9, 11]. The quality and quantity of extracted nucleic acids

were controlled by gel electrophoresis and NanoDrop 2000 UV spectrophotometer (Thermo

195 Scientific).

196 Library preparation was performed by two-step PCR amplification using 16S universal

197 primers targeting the V3–V4 region of the bacterial 16S ribosomal DNA (rDNA), as described

198 previously [10]. The resulting amplicon of approximately 467 base pairs was sequenced using

2 x 300 paired-end MiSeq kit V3. For each sample, a sequencing library was generated by the
 addition of sequencing adapters. The detection of the sequencing fragments was performed

201 using MiSeq Illumina technology.

202 The targeted metagenomic sequences from microbiota were analyzed using the

203 bioinformatics pipeline established by Vaiomer based on the Find, Rapidly, OTUs with Galaxy

204 Solution guidelines. Briefly, after demultiplexing the barcoded Illumina paired reads, single-

205 read sequences were cleaned and paired for each sample independently into longer

206 fragments. Operational taxonomic units (OTUs) were produced via single-linkage clustering

using the Swarm algorithm and its adaptive sequence agglomeration [12]. The taxonomic

assignment was performed against the Silva v132 database to determine taxonomic profiles.

209 The following specific filters were applied for this analysis to obtain the best results: (1) the

last ten bases of reads R1 were removed; (2) the last 40 bases of reads R2 were removed; (3)

amplicons with a length of <350 or >500 nucleotides were removed; (4) OTUs with

abundance <0.005% of the whole dataset abundance were removed. To ensure the low impact

of the potential DNA contamination from the environment and especially from reagents,

214 negative controls were added and carried over throughout the 16S rRNA gene sequencing

215 pipeline. Negative controls were performed for the DNA extraction and amplification steps

216 with molecular grade water as starting material. Positive controls with a mock community

217 were also added during the sequencing library preparation.

218 Non-targeted metabolomics

219 Firstly, methanol was mixed with plasma samples (3:1, v/v) for viruses' inactivation. Then, samples 220 were vortexed (15 sec), maintained cold for 5 min, centrifuged (16000 g, 20 min, 4°C), and frozen 221 (-80°C) before being sent to the Center for Metabolomics and Bioanalysis (CEU-San Pablo 222 University, Pozuelo de Alarcón, Spain). On the day of analysis, the samples were correctly 223 processed and subsequently analyzed by gas chromatography-mass spectrometry (GC-MS) and 224 liquid chromatography-mass spectrometry (LC-MS) with positive and negative electrospray 225 ionization (ESI). Quality controls were prepared by pooling and mixing equal volumes of each 226 corresponding sample independently for each analytical platform (full description in

227 **Supplementary_file_1**).

228 For the deconvolution and identification process in GC-MS, MassHunter Quantitative Unknown

analysis (B.07.00, Agilent) was used. Alignment was carried out with MassProfiler Professional

software (version 13.0, Agilent), and Masshunter Quantitative Analysis (version B.07.00, Agilent)

- 231 was used for peak integration. In LC-MS, the Molecular Feature Extraction and the Recursive
- Feature Extraction algorithms in the MassHunter Profinder software (B.08.00, Agilent) were used
- for deconvolution, peak integration, and alignment of the raw data (more details are available in
- 234 **Supplementary_file_1**).

235 Statistical analysis

For the descriptive study, quantitative variables were expressed as median (interquartile
range) and categorical variables as absolute count (percentage). When comparing data
between groups, we used Fisher's exact test for categorical and unpaired Wilcoxon rank-sum
test for continuous variables.

Regarding the metagenomics data, richness (Chao1 estimator), alpha diversity (Shannon and 240 Simpson index), and beta diversity (Weighted Unifrac distance, Bray-Curtis dissimilarity, 241 Jaccard index) of bacterial communities were calculated (Vegan package V. 2.5-7). Richness 242 and alpha diversity indexes were analyzed in association with hepatic decompensation, here 243 considered as an independent variable, by the Wilcoxon rank-sum test and multivariable 244 245 generalized linear model (GLM) with a gamma distribution, unadjusted and adjusted by HIV 246 coinfection (included as covariate in the model). Besides, we compared beta diversity 247 between groups by using principal coordinates analysis (PCoA) plots and permutational MANOVA. 248

For analyzing differences in the relative abundance of OTUs between groups, we first 249 normalized the initial data at each taxonomic level and filtered those taxa that did not reach 250 251 the minimum abundant level for the analysis (at least appeared in 10% of the samples). 252 Subsequently, we carried out univariable and multivariable analyses. Univariable analysis was performed using the Wilcoxon rank-sum test, a non-parametric test that compares the 253 relative abundances of bacterial taxa between groups. The false discovery rate (FDR) was 254 applied to account for multiple comparison, and adjusted p-values (q-values) were calculated 255 256 according to the Benjamini-Hochberg method. Those taxa with p<0.05 and q<0.150 were included in the multivariable models. Multivariable analyses were carried out using the 257 aldex.glm function from the ALDEx2 package (v. 1.22.0), and HIV coinfection was included as 258 a covariate. 259

- 260 Finally, we selected the bacterial taxa significantly different in the relative abundance
- 261 between groups, and we estimated the correlation with plasma metabolomic data from GC-
- MS, LC-MS ESI+, and LC-MS ESI- using the Spearman rank order correlation test. The
- 263 correlations were considered relevant when r>0.3 or r<-0.3 and q<0.150.
- All the analyses were carried out by using R statistical package (R Foundation for Statistical
- 265 Computing, Vienna, Austria, v. 4.0.5).

268 **Results**

269 Characteristics of the study population

- A total of 88 patients were included, 61 with HIV, whose characteristics stratified by their
- stage of cirrhosis (compensated vs. decompensated) are shown in **Table 1**. Among patients
- with compensated cirrhosis (n=75), the mean age was 53.1 years, and 65% were male.
- 273 Patients with decompensated cirrhosis (n=13) had a mean age of 52.1 years, and 92.3% were
- male. Of note, decompensated patients were less frequently coinfected with HIV (p = 0.019).

275 Microbiome analysis

A) <u>Richness and alpha diversity</u>

- 277 Decompensated patients showed lower richness at phylum (Chao1, p=0.032) and class levels
- 278 (Chao1, p=0.020) than compensated patients (Figure1). Regarding alpha diversity,
- decompensated patients showed lower levels of Shannon (p=0.005) and Simpson indexes
- 280 (p=0.003) at the phylum level than compensated patients (**Figure1**).
- After adjustment for HIV coinfection in a gamma GLM model, we found that decompensated
- patients had lower levels of Chao1 estimator at the phylum (adjusted arithmetic mean ratio
- (aAMR)=0.85, p=0.021) and class level (aAMR=0.85, p=0.019) than compensated patients.
- 284 Regarding alpha diversity, decompensated patients showed lower levels of Shannon
- (aAMR=0.80, p=0.005) and Simpson indexes (aAMR=0.83, p=0.006) at the phylum level than
- compensated patients (**Supplementary_file_2**).

287 B) <u>Beta diversity</u>

- 288 Beta-diversity was significantly different between compensated and decompensated patients,
- finding lower beta-diversity at the phylum level (Jaccard: p=0.049), class level (Weighted
- Unifrac: p=0.040, Bray-Curtis: p=0.017, Jaccard: p=0.028), and order level (Weighted Unifrac:
- p=0.016, Bray-Curtis: p=0.047) in decompensated patients, as determined using PCoA plots

292	and permutational MANOVA. In addition, these significant differences were maintained when
293	models were adjusted by HIV coinfection at the phylum level (Jaccard: adjusted p=0.046),
294	class level (Weighted Unifrac: adjusted p=0.033, Bray-Curtis: adjusted p=0.018), and order
295	level (Weighted Unifrac: adjusted p=0.019, Bray-Curtis: adjusted p=0.048) (Figure2,
296	Supplementary_file_3).
297	C) <u>Relative abundances</u>
298	We assessed the differences in the relative abundance at all taxonomic levels between
299	decompensated and compensated patients. Decompensated patients had a higher relative
300	abundance of the phylum Proteobacteria (p=0.004), the class Alphaproteobacteria (p \leq 0.001),
301	the orders Sphingomonadales ($p \le 0.001$) and Oceanospirillales ($p = 0.047$), families
302	Sphingomonadaceae (p=0.002), Paenibacillaceae (p=0.038) and Microbacteriaceae (p=0.043),
303	and genus <i>Bradyrhizobium</i> (p=0.001), <i>Sphingomonas</i> (p=0.009) and <i>Rhodococcus</i> (p=0.027)
304	than compensated patients. However, only the phylum Proteobacteria (q=0.037), the class
305	Alphaproteobacteria (q=0.006), the order Sphingomonadales (q=0.050), family
306	Sphingomonadaceae (q=0.090) and genus Bradyrhizobium (q=0.087) were considered
307	relevant after adjusting for multiple comparisons (FDR, q<0.150) (Table 2). When HIV
308	coinfection was taken into account for adjusting the models by ALDEx2, a higher relative
309	abundance of Proteobacteria (p=0.012), Alphaproteobacteria (p=0.016), and
310	Sphingomonadales (p=0.050) remained significantly associated with hepatic decompensation.
311	Boxplots for the relative abundances of these significant bacterial taxa are shown in
312	Supplementary_file_4.
313	Correlation analysis with metabolomic data
314	The correlation between bacterial taxa related to hepatic decompensation and metabolomic
315	data was studied. Regarding GC-MS data, we observed a significant positive correlation of the

316 phylum *Proteobacteria* with ethanolamine and oleic acid (r=0.330, p=0.005, q=0.115 and

- r=0.302, p=0.004, q=0.115, respectively) and a significant negative correlation with p-cresol
- 318 (r=-0.308, p=0.006, q=0.115). In addition, the order *Sphingomonadales* was negatively
- correlated with p-cresol (r=-0.354, p=0.001, q=0.112) (**Figure3, Supplemental File 5**).
- 320 Regarding LC-MS data, we found a significant negative correlation between the order
- 321 *Sphingomonadales* and p-cresol (r=-0.367, p=0.001, q=0.122) (**Figure 3**,
- 322 Supplementary_file_5).

325 **Discussion**

We compared the blood microbiome between HCV-infected patients with decompensated and compensated cirrhosis, finding lower alpha and beta diversity richness in the first ones. We also found that the relative abundance of Proteobacteria, Alphaproteobacteria, and Sphingomonadales was higher in decompensated patients. The dysbiosis of the blood microbiome was accompanied by changes in metabolites related to liver reparation processes and microbiota fermentation.

332 Although several studies have previously investigated the blood microbiome in cirrhosis, few articles have described its role among HCV-infected cirrhotic patients. Recently, Gedgaudas et 333 334 al. found that circulating microbiome profiles in patients with cirrhosis were distinct from those of healthy individuals, with enrichment of the genera Bacteroides, Escherichia/Shigella, 335 336 and *Prevotella* in patients with portal hypertension [13]. However, this study included patients with cirrhosis of different etiologies and analyzed plasma instead of whole blood 337 [13]. Traykova *et al.* studied the blood microbiome in nine patients with decompensated 338 cirrhosis compared to controls, finding that the bacterial microbiome is related to changes in 339 systemic vascular resistance and cardiac outcomes [7]. However, they only screened for 53 340 341 specific bacteria from the gut in the blood [7]. Moreover, our group previously found an association between specific bacterial taxa before HCV therapy, such as *Corynebacteriales* and 342 Massilia, and a decrease in HVPG in patients with HCV-related cirrhosis after direct-acting 343 344 antiviral therapy for HCV [14]. Thus, to our knowledge, this is the first study in which the 345 circulating microbiome from patients with compensated and decompensated HCV-related 346 cirrhosis has been compared, providing new insight into the potential mechanisms underlying 347 this liver injury status.

In our study, patients with decompensated cirrhosis had lower richness and alpha diversity
for different taxonomic ranks than patients with compensated cirrhosis. These findings are

consistent with previous data supporting that less diverse gut microbiome ecosystems are 350 351 associated with poorer body health status, probably because reduced species diversity leads to lower efficient systems [15]. Regarding viral hepatitis and gut microbiome, a less diverse 352 microbiome has been previously described in the gut of cirrhotic patients with hepatitis B and 353 C compared to healthy controls, finding significant differences in the microbiota community 354 between groups [16, 17]. Moreover, an improvement in gut microbiota diversity was also 355 356 observed in responders achieving a sustained virological response after anti-HCV therapy; 357 however, patients with more advanced fibrosis stages showed lower improvement [16]. In this line, while changes in the diversity of gut microbiome are getting deeply studied, there is 358 scarce data about diversity changes in blood microbiome among patients with viral hepatitis. 359 360 In a recent study, a trend towards lower bacterial diversity with worse disease stage was 361 described in the context of hepatitis B and D infection [18], which is consistent with what we 362 observed in patients with HCV-related cirrhosis.

Regarding the beta diversity, which represents the number of overlapping taxa between 363 samples, microbiome signature differences between compensated and decompensated 364 patients were consistently found for phylum, class, and order taxonomic ranks, and 365 366 corroborated by several indexes, with PCoA helping us to visualize these differences. In 367 previous studies, separate clustering between patients with liver disease induced by viral hepatitis C and healthy controls was described in the gut [19]. However, similar to alpha 368 diversity, information in the literature is sparse, and to our knowledge, this is the first report 369 studying differences in beta diversity between different cirrhosis stages in blood. 370

We also detected an association between a higher relative abundance of Proteobacteria,
Alphaproteobacteria, and Sphingomonadales and hepatic decompensation. Proteobacteria has
been described as a potential microbial signature of dysbiosis and disease risk [20]. A study
by Sun et al. documented that the phylum Proteobacteria, among others, was increased in

375	patients with chronic B cirrhosis [17]. Alphaproteobacteria, a class rank belonging to the
376	phylum Proteobacteria, is classified as one of the most diverse bacterial subdivisions
377	influencing host-cell proliferation [21]. The order Sphingomonadales, which is part of the
378	class Alphaproteobacteria, appears to be relatively more abundant in patients with hepatic
379	decompensation. Bacteria from the Sphingomonadales order are known to have
380	lipoxygenases that may have a vital role in bacteria-host signaling [22]. All these findings in
381	the literature support the significant association with hepatic decompensation found in our
382	study. In regards to the Sphingomonadaceae family, we found a trend of association between
383	the relative abundance of this family and hepatic decompensation.
384	Dysbiosis in environments such as the gut or oral cavity often goes hand in hand with
385	metabolic changes and disease progression [23]. Regarding the blood, we observed that
386	metabolic changes also accompanied microbiome dysbiosis. The phylum Proteobacteria was
387	directly associated with two metabolites in this study, ethanolamine and oleic acid. Firstly,
388	ethanolamine, a source of nitrogen and carbon by diverse bacteria, has been associated with
389	liver reparation processes in the damaged liver [24]. Secondly, oleic acid is a
390	monounsaturated fatty acid with numerous beneficial properties in various animal and
391	vegetable sources. In liver injuries, oleic acid recruitment from other tissues has been
392	described as one of the rescue systems [25]. Some studies have observed its role in inhibiting
393	chemotaxis and attenuating inflammation [26]. Additionally, we found an inverse correlation
394	of the relative abundance of the phylum Proteobacteria, the order Sphingomonadales, and the
395	family Sphingomonadaceae with the p-cresol, being found by different analytical platforms
396	(GC-MS and LC-MS). P-cresol is originated by fermentation from the microbiota. Based on
397	previous microbiological studies, since bacteria of the phylum Proteobacteria are Gram-
398	negative, their cell envelope is more sensitive to p-cresol, so it is consistent that in the absence
399	of this metabolite, these taxa could grow freely in the blood and promote dysbiosis [27].
400	Besides, Ikematsu <i>et al.</i> , in forensic autopsy cases, suggested that low levels of p-cresol in

401 blood could be explained by an accumulation of p-cresol in the liver in cases of liver diseases402 [28].

403 Additionally, it is crucial to note that this study was performed using a strict contamination-404 aware approach. Firstly, any potential contamination by needle with the skin microbiome was 405 prevented by the high volume of blood withdrawn. Secondly, positive and negative controls 406 were used throughout the sequencing pipeline in order to control any impact of the environ-407 ment on the results. Thirdly, to avoid possible confusion with HIV coinfection, multivariate models including HIV status as a covariate were carried out, controlling the possible con-408 founding effects of HIV-coinfection. Finally, adjustment for multiple comparison was per-409 formed, avoiding false significant associations. All of these approaches provide robustness to 410 411 our data. The following considerations should be taken into account for a correct interpretation of the 412 results. Firstly, this study had a cross-sectional design; therefore, it does not allow us to 413 determine the causal relationship of the findings. Secondly, the sample size was limited, which 414 415 could restrict the statistical power to detect other significant differences in bacterial taxa 416 between groups. Moreover, we could not carry out the statistical analysis separately for HCV-417 monoinfected and HIV/HCV-coinfected patients due to the limited sample size. Nevertheless,

418 possible confusion with HIV coinfection was ruled out by including HIV status as a covariate in419 multivariate models.

420 **Conclusions**

In conclusion, blood microbial diversity was significantly decreased in patients with
decompensated HCV-related cirrhosis, who presented an enrichment of Proteobacteria,
Alphaproteobacteria, and Sphingomonadales, compared to patients with compensated
cirrhosis. The dysbiosis of the blood microbiome was accompanied by metabolomic changes.

- 425 Further studies are needed to decipher the impact that blood microbial dysbiosis could have
- 426 on these patients and strategies to correct it.

428 Abbreviations

- 429 aAMR: Adjusted arithmetic mean ratio
- 430 AMR: Arithmetic mean ratio
- 431 ART: Antiretroviral therapy
- 432 CTP: Child-Turcotte-Pugh
- 433 ESI: Electrospray ionization
- 434 FC: Fold Change
- 435 FDR: False discovery ratio
- 436 GC-MS: Gas chromatography-mass spectrometry
- 437 GLM: Generalized linear model
- 438 HCC: Hepatocellular carcinoma
- 439 HCV: Hepatitis C virus
- 440 HIV: Human immunodeficiency virus
- 441 HVPG: Hepatic venous pressure gradient
- 442 INR: International normalized ratio
- 443 LC-MS: Liquid chromatography-mass spectrometry
- 444 MANOVA: Multivariate analysis of variance
- 445 OTU: Operative taxonomic Unit
- 446 PCoA: Principal coordinates analysis
- 447 PCR: Polymerase chain reaction

448

450 **References**

- [1] D'Amico G, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis. J
 Hepatol 2022; 76:202-207.
- 453 [2] Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383:1749-1761.
- 454 [3] Sandler NG, Koh C, Roque A *et al.* Host response to translocated microbial products
- 455 predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220456 1230, 1230 e1221-1223.
- 457 [4] Ishizaka A, Koga M, Mizutani T *et al.* Unique Gut Microbiome in HIV Patients on
- Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation. Microbiol
 Spectr 2021; 9:e0070821.
- [5] Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to
 Hepatic Disorders. Gastroenterology 2020; 159:849-863.
- [6] Jalan R, Gines P, Olson JC *et al.* Acute-on chronic liver failure. J Hepatol 2012; 57:13361348.
- 464 [7] Traykova D, Schneider B, Chojkier M, Buck M. Blood Microbiome Quantity and the
- Hyperdynamic Circulation in Decompensated Cirrhotic Patients. PLoS One 2017;
 12:e0169310.
- 467 [8] Alvarez-Silva C, Schierwagen R, Pohlmann A *et al.* Compartmentalization of Immune
- 468 Response and Microbial Translocation in Decompensated Cirrhosis. Front Immunol 2019;
 469 10:69.
- 470 [9] Anhe FF, Jensen BAH, Varin TV *et al.* Type 2 diabetes influences bacterial tissue 471 compartmentalisation in human obesity. Nat Metab 2020; 2:233-242.
- [10] Lluch J, Servant F, Paisse S *et al.* The Characterization of Novel Tissue Microbiota Using an
 Optimized 16S Metagenomic Sequencing Pipeline. PLoS One 2015; 10:e0142334.
- [11] Schierwagen R, Alvarez-Silva C, Servant F *et al.* Trust is good, control is better: technical
 considerations in blood microbiome analysis. Gut 2020; 69:1362-1363.
- 476 [12] Escudie F, Auer L, Bernard M *et al.* FROGS: Find, Rapidly, OTUs with Galaxy Solution.
 477 Bioinformatics 2018; 34:1287-1294.
- [13] Gedgaudas R, Bajaj JS, Skieceviciene J *et al.* Circulating microbiome in patients with portal
 hypertension. Gut Microbes 2022; 14:2029674.
- 480 [14] Virseda-Berdices A, Brochado-Kith O, Diez C *et al.* Blood microbiome is associated with
- changes in portal hypertension after successful direct-acting antiviral therapy in patients with
 HCV-related cirrhosis. J Antimicrob Chemother 2022; 77:719-726.
- [15] Larsen OFA, Claassen E. The mechanistic link between health and gut microbiota
 diversity. Sci Rep 2018; 8:2183.

- [16] Chuaypen N, Jinato T, Avihingsanon A *et al.* Improvement of Gut Diversity and
- 486 Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or
- 487 Without Human Immunodeficiency Virus Coinfection. J Infect Dis 2021; 224:1410-1421.
- [17] Sun X, Chi X, Zhao Y *et al.* Characteristics and Clinical Significance of Intestinal Microbiota
 in Patients with Chronic Hepatitis B Cirrhosis and Type 2 Diabetes Mellitus. J Diabetes Res
 2022; 2022: 1826181.
- [18] Townsend EC, Zhang GY, Ali R *et al.* Microbial Translocation in the Context of Hepatitis B
 Infection and Hepatitis D Infection. Open Forum Infect Dis 2021; 8:ofaa496.
- [19] Ullah N, Kakakhel MA, Khan I *et al.* Structural and compositional segregation of the gut
 microbiota in HCV and liver cirrhotic patients: A clinical pilot study. Microb Pathog 2022;
 171:105739.
- 496 [20] Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut
 497 microbiota. Trends Biotechnol 2015; 33:496-503.
- 498 [21] Ettema TJ, Andersson SG. The alpha-proteobacteria: the Darwin finches of the bacterial
 499 world. Biol Lett 2009; 5:429-432.
- 500 [22] Kurakin GF, Samoukina AM, Potapova NA. Bacterial and Protozoan Lipoxygenases Could
- be Involved in Cell-to-Cell Signaling and Immune Response Suppression. Biochemistry (Mosc)
 2020; 85:1048-1071.
- [23] Wilmanski T, Rappaport N, Earls JC *et al.* Blood metabolome predicts gut microbiome
 alpha-diversity in humans. Nat Biotechnol 2019; 37:1217-1228.
- [24] Murakami T, Nagamura Y, Hirano K. Ethanolamine stimulates repair processes in acute
 CCl4 damage of mouse liver. Toxicol Lett 1998; 94:137-144.
- 507 [25] Piccinin E, Cariello M, De Santis S *et al.* Role of Oleic Acid in the Gut-Liver Axis: From Diet 508 to the Regulation of Its Synthesis via Stearoyl-CoA Desaturase 1 (SCD1). Nutrients 2019; 11.
- 509 [26] Malawista SE, de Boisfleury Chevance A, van Damme J, Serhan CN. Tonic inhibition of 510 chemotaxis in human plasma. Proc Natl Acad Sci U S A 2008; 105:17949-17954.
- 511 [27] Passmore IJ, Letertre MPM, Preston MD *et al.* Para-cresol production by Clostridium
- difficile affects microbial diversity and membrane integrity of Gram-negative bacteria. PLoS
 Pathog 2018; 14:e1007191.
- 514 [28] Ikematsu N, Kashiwagi M, Hara K *et al.* Diagnostic meaning of blood p-cresol
- 515 concentration in forensic autopsy cases. Leg Med (Tokyo) 2018; 34:27-35.
- 516

518 **Tables**

Table 1. Clinical and epidemiological characteristics of patients with HCV-related advancedcirrhosis.

521

Characteristic	Compensated	Decompensated	P-value
No.	75	13	
Age (years)	53.1 [50.5-56.1]	52.1 [46.6-56.4]	0.301
Gender (male %)	49/75[65.33%]	12/13[92.3%]	0.058
BMI (kg/m ²)	24.2[22.1-27.7]	26.7[23.9-27.9]	0.198
Smoker			0.389
Never	16/75[21.3%]	1/13 [7.7%]	
> 6 months	17/75 [22.7%]	5/13 [38.5%]	
Currently	42/75 [56%]	7/13 [53.9%]	
Alcohol intake			0.376
Never	39/75 [52.0%]	5/13 [38.5%]	
> 6 months	31/75 [41.3%]	6/13 [46.2%]	
Currently	5/75 [6.7%]	2/13 [15.4%]	
IVDU	44/75[58.7%]	8/13[61.5%]	0.999
HCV genotype 1	51/75[68.0%]	7/11[57.1%]	0.743
HCV viral load (log10)	6.2[5.7-6.6]	5.79 [5.2-6.2]	0.053
Previous anti-HCV treatment	36/75[48.0%]	7/13 [53.9%]	0.770
Statins	9/75[12.0%]	0/13 [0%]	0.345
Coinfection (HIV)	56/75[74.7%]	5/13 [38.5%]	0.019
CD4 ⁺ /mm ³	446.5[239.3-719.5]	378.0[164.0-685.0]	0.502
Nadir CD4 cells	119.0[63.0-232.5]	207.0[144.0-300.0]	0.131
AIDS	37/56[66.1%]	3/5[60.0%]	0.999

522

523 **Statistics**: Continuous variables were expressed as median [interquartil range], and p-values

524 were calculated by the Wilcoxon rank-sum test. Categorical variables were expressed as

525 absolute count [percentage], and p-values were calculated by the Fisher exact test.

526 **Abbreviations**: CTP, Child-Turcotte-Pugh; BMI, Body mass index; IVDU, Intravenous drugs

527 user; HCV, Hepatitis C virus; HIV, Human immunodeficiency virus; AIDS, Acquired immune

528 deficiency syndrome.

Table 2. Association between relative abundance of blood bacterial taxa and HCV-related decompensated cirrhosis.

Bacterial taxa		Univariate		Multivariate	
Taxonomic rank	Таха	p-value	FDR	Estimate	p-value
Phylum	Proteobacteria	0.004	0.037	1.490	0.012
Class	Alphaproteobacteria	≤ 0.001	0.006	2.340	0.016
Ondon	Sphingomonadales	≤ 0.001	0.036	4.003	0.050
Urder	Oceanospirillales	0.047	0.810	1.307	0.417
	Sphingomonadaceae	0.002	0.090	3.693	0.075
Family	Paenibacillaceae	0.038	0.759	1.030	0.515
	Microbacteriaceae	0.043	0.759	2.410	0.214
	Bradyrhizobium	0.001	0.087	1.612	0.376
Genus	Sphingomonas	0.009	0.377	2.873	0.174
	Rhodococcus	0.027	0.623	2.518	0.145

Statistics: P-values were calculated by univariate (Wilcoxon rank-sum test) and multivariate models (ALDEx2 package) adjusting by HIV 534 coinfection as a covariate. FDR was calculated by Benjamini and Hochberg correction.

Abbreviations: FDR, false discovery ratio; FC, fold change; HIV, Human immunodeficiency virus.

536 Figures

Figure1. Representation of richness and alpha-diversity indexes for patients with

compensated and decompensated cirrhosis. A) Chao1 estimator: it is calculated by taking the number of different species and also considering as relevant the number of species that were detected once (singletons) or twice (doubletons). B) Shannon index: it is based on the formula to describe entropy and how difficult it is to predict the next microbe detection when the diversity is high. C) Simpson index: it measures the probability that two individuals randomly selected from a sample will belong to the same taxa. Differences between groups were calculated by using Wilcoxon signed-rank test and expressed as p-values.



545

Figure2. Principal coordinates analysis (PCoA) representing the beta diversity for patients
with compensated and decompensated cirrhosis. Statistics: P-values were calculated from a
permutational univariate and multivariate analysis of variance adjusted for HIV-coinfection.



- **Figure3**. Correlation between blood significant bacterial taxa and plasma metabolites.
- 553 Statistics: Direct correlations are shown in blue while inverse correlations are shown in red.
- Asterisks indicate those correlations with a value of p-value<0.05 and q-value ≤ 0.15 (q-values)
- 555 (FDR) were calculated from Spearman correlation p-values.

